In its first-ever assessment of biomedical institutions around the world, based upon published research in a targeted set of high-quality scientific journals, the 2019 Nature Index ranked University of California San Diego ninth among the top 200 institutions in biomedical sciences worldwide.
The Health Cyberinfrastructure (CI) Division of the San Diego Supercomputer Center (SDSC) at the University of California San Diego, has partnered with Microsoft Azure Cloud Services (Azure) to expand its portfolio of cloud services.
A team of scientists at Scripps Institution of Oceanography at the University of California San Diego and the J. Craig Venter Institute (JCVI) has developed a new way to produce kainic acid, a natural seaweed neurochemical and powerful reagent used in brain research.
U.S. News & World Report today released its 2020 guidebook that ranks the nation’s top graduate programs and professional schools, giving high marks to UC San Diego’s innovative programs.
Mining a large database of adverse reactions to medications, UC San Diego researchers found that people who took proton pump inhibitors (e.g., Prilosec, Nexium) for heartburn and acid reflux were more likely to experience kidney disease than people who took other forms of antacid.
University of California San Diego, in a collaborative agreement with Leica Microsystems, Inc., hosted a signing ceremony to inaugurate a new Leica Microsystems Center of Excellence on the School of Medicine campus.
An international group that includes researchers at University of California San Diego School of Medicine has identified 124 genetic variants associated with a person’s willingness to take risks, as reported in a study published January 14, 2019 in Nature Genetics.
After living with debilitating phantom leg pain for 18 years, Raul Silva is excited about a new dorsal root ganglion (DRG) stimulation device that erased his pain during a testing phase at UC San Diego Health, one of the only health care providers in the region offering the device.
Researchers spent two years testing chemical compounds for their ability to inhibit the malaria parasite at an earlier stage in its lifecycle than most current drugs, revealing a new set of chemical starting points for the first drugs to prevent malaria instead of just treating the symptoms.
In lab and mouse experiments, UC San Diego School of Medicine researchers developed a method to leverage B cells to manufacture and secrete tumor-suppressing microRNAs.